← Library

The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of a variety of biomarkers, companion diagnostics (CDx) and complementary diagnostics.

 

Having supported immuno-oncology drug development from preclinical studies to clinical trials, and post-market introduction of the therapy and associated diagnostics, global contract research organizations (CROs) like Covance have a unique perspective on the novel developments in this field. This whitepaper shares some of the highlights in personalized medicine Covance has supported recently as new immuno-oncology therapies have emerged.

 

In this white paper, you’ll learn about:

  • Programmed death-ligand 1 (PD-L1) expression patterns, assay formats and method comparison studies
  •  The current use of companion and complementary diagnostics
  •  Commercial implications and trends
  •  Advances and applications for genomic biomarker assays
  • Future considerations, from preclinical studies to commercialization of the therapy and relevant diagnostic assays